COMP <GO>
ONCO vs CVKD // NET PROFIT MARGIN
Onconetix Inc. (NASDAQ) VS. Cadrenal Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ONCO 2
— CVKD 1
■ METRIC PARITY
LAST: $0.54 (-3.24%) • MKT CAP: $3.3M
net-margins
-60.00%
LAST: $1.04 (+5.58%) • MKT CAP: $3.5M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONCO VS. CVKD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONCO | CVKD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ONCO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 46.6 | +1.70 | ONCO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.3M | $3.5M | -$204.2K | CVKD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONCO REV | CVKD REV | ONCO GROSS % | CVKD GROSS % | ONCO FCF | CVKD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $815.4K | $37.7M | 77.6% | — | -$9.7M | -$12.6M |
| FY 2024 | $2.5M | $30.7M | 41.8% | — | -$10.5M | -$7.4M |
| FY 2023 | $58.5K | $21.4M | — | — | -$13.6M | -$3.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONCO // BETA —
CVKD // BETA —